Drug intelligence / Profile preview

chloramphenicol + gentamycin + metronidazole

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Intravenous, Intramuscular, Intraarticular, Intraperitoneal, Oral
01

Overview

This is a combination of three antibiotics—chloramphenicol, gentamycin, and metronidazole—each with distinct mechanisms of action. Chloramphenicol is a broad-spectrum antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, primarily exerting a bacteriostatic effect[1][4]. Gentamycin (an aminoglycoside) inhibits protein synthesis by binding to the 30S ribosomal subunit and is mainly bactericidal against gram-negative bacteria[4][5]. Metronidazole is a nitroimidazole antibiotic that disrupts DNA synthesis in anaerobic bacteria and protozoa, leading to cell death[2][4][5]. This combination may be used for severe mixed infections where both aerobic and anaerobic coverage are required or in veterinary medicine for complex infections such as peritonitis or septic arthritis[3][5].

02

Targets

NeuraminidaseBacterial 50S ribosomal subunitBacterial Ribosome

Beyond the preview

Go deeper on chloramphenicol + gentamycin + metronidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on chloramphenicol + gentamycin + metronidazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call